Animalcare Group plc (LSE:ANCR) has acquired the VHH NGF programme and related assets from Orthros Medical for €0.7 million, securing full ownership of the technology’s development and commercialization. The deal supports Animalcare’s strategy to strengthen its pipeline of innovative treatments, particularly targeting osteoarthritis-related pain in companion animals. By eliminating future financial commitments tied to the prior licensing agreement, the acquisition also provides greater flexibility and unlocks opportunities to explore broader applications of VHH technology across multiple species and conditions. In collaboration with 272Bio, Animalcare is progressing its antibody programmes, positioning itself to access some of the largest animal health markets worldwide.
The company’s outlook reflects a balance of strengths and risks. While financial stability and strategic acquisitions enhance its long-term growth prospects, bearish technical indicators and valuation concerns temper short-term expectations.
About Animalcare
Animalcare Group plc is an AIM-listed veterinary sales and marketing company headquartered in the UK. Operating across seven European countries, as well as Australia, New Zealand, and the UAE, it exports products to around 40 international markets. The business focuses on expanding its portfolio through product development, strategic partnerships, and acquisitions.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply